Corporate Finance

Morocco Strategic Minerals reports high-grade copper and gold, but the real story lies in its calculated pivot to a nation courting global mining investment.

Two popular Kingston restaurants are for sale under a trustee. The deal reveals the precarious state of the franchise model and challenges facing our economy.

A small community lender just earned a Wall Street-grade rating, defying a long-held industry belief. Here’s how Momentus Securities and City First Enterprises cracked the code.

A breakthrough in robotic touch from Tacta Systems promises to automate tasks once thought impossible, signaling a potential turning point for reshoring.

In a tough fundraising climate, LLCP's oversubscribed $2 billion fund reveals a market hungry for proven strategies and the resilient lower middle market.

A $25M deal for a plant protein facility is more than just a project; it's a blueprint for Alberta's economic diversification and a new global food chain.

With fresh capital and key regulatory approvals, Median Technologies is launching its AI lung cancer tool, powered by a stable and record-setting iCRO business.

In a frozen real estate market, Townsend's $2 billion fund provides a critical thaw, buying assets at a discount and offering a lifeline to investors.

Beyond malls and movies, urban Indians are seeking pottery, sailing, and perfume-making. A look at the tech-driven shift to local, curated experiences.

A Pittsburgh startup just secured major funding to fix a 60-year-old problem in EMS, potentially saving millions from secondary injuries during ambulance rides.

Silver Hill's massive fundraise isn't just a bet on oil and gas. It's a strategic play on energy security, AI's power thirst, and a slower-than-advertised transition.

Backed by Mark Cuban, Kind Designs uses 3D printing to create seawalls that double as marine habitats, merging climate resilience with ecological restoration.

With a fresh $4.2M, Proaction is replacing call centers with AI agents, targeting the inefficiencies of a massive, multi-billion dollar legacy industry.

With a $40M raise and a team of heavy-hitters, ORANGE JUICE is launching a permanent capital firm to acquire and hold businesses, backed by a Bitcoin treasury.

Defying a bear market, Pepeto's presale raises over $10M with promises of Layer 2 tech. But can its product-first approach overcome its anonymous leadership?

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

HarbourVest's $4.75B fund signals a major trend: investors are bypassing old models for direct access to deals in AI and tech. What does this mean for you?

With a new name and $35M in fresh funding, Allotera Therapeutics is doubling down on a pivotal trial for Sofi-cel, a therapy aimed at solving a tough T-cell cancer.

As private equity faces a liquidity crunch, Patria Investments' oversubscribed secondary fund reveals a winning strategy: targeting smaller, overlooked deals.

Beyond software, a new breed of venture capital is funding America's industrial rebirth, pouring millions into AI, robotics, and the factories of the future.